Santhera Pharmaceuticals Holding AG

Swiss Stock Exchange SANN.SW

Santhera Pharmaceuticals Holding AG Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -21.43 M

Santhera Pharmaceuticals Holding AG Net Cash Used For Investing Activities is USD -21.43 M for the year ending December 31, 2023, a -404.03% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Santhera Pharmaceuticals Holding AG Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -4.25 M, a -5,722.13% change year over year.
Santhera Pharmaceuticals Holding AG Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD 75.63 K, a -95.72% change year over year.
Santhera Pharmaceuticals Holding AG Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD 1.77 M, a -38.68% change year over year.
Santhera Pharmaceuticals Holding AG Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD 2.88 M, a 148.01% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

Swiss Stock Exchange: SANN.SW

Santhera Pharmaceuticals Holding AG

CEO	Mr. Dario Eklund
IPO Date	Nov. 3, 2006
Location	Switzerland
Headquarters	Hohenrainstrasse 24
Employees	44
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Key trends

Past 5 years